Related Experiment Video

Updated: Jun 26, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
10:36

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in

Elsa Isingrini1, Thomas Desmidt, Catherine Belzung

  • 1UMR INSERM U & CNRS FRE, CHRU de Tours, France.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 8, 2009
PubMed

Insights

Vascular issues link elderly depression and Alzheimer's disease (AD). Treatments targeting endothelial dysfunction, like certain medications and nitric oxide pathways, may help manage both conditions.

Area of Science:

  • Geriatrics
  • Neuroscience
  • Cardiology

Background:

  • Depression and Alzheimer's disease (AD) are common in the elderly.
  • Vascular diseases and risk factors are linked to both depression and AD.
  • Endothelial dysfunction is implicated in depression's neurobiology and AD's amyloid deposition.

Purpose of the Study:

  • To explore the connection between vascular factors, depression, and Alzheimer's disease.
  • To investigate the role of endothelial dysfunction in the comorbidity of depression and AD.
  • To review potential therapeutic targets, including vascular disease treatments and signaling pathways.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the impact of antidepressants on endothelial function.
  • Examination of the effects of vascular disease medications on depressive symptoms and AD pathology.

Main Results:

  • Vascular diseases and risk factors contribute to the coexistence of depression and AD.
  • Endothelial dysfunction is a key factor in the neurobiology of depression and amyloid deposition in AD.
  • Antidepressants, calcium-channel blockers, ACE inhibitors, and statins show effects on depressive symptoms or AD.
  • Nitric oxide and VEGF signaling pathways show therapeutic potential.

Conclusions:

  • Vascular health is critical in managing elderly mental health, particularly depression and AD.
  • Targeting endothelial dysfunction and related pathways offers a promising therapeutic strategy for both conditions.
  • Further research into vascular-centric treatments could improve outcomes for patients with depression and AD.

More Related Videos

Isolation and Functional Analysis of Arteriolar Endothelium of Mouse Brain Parenchyma06:40

Isolation and Functional Analysis of Arteriolar Endothelium of Mouse Brain Parenchyma

Published on: March 11, 2022

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...